Year: 2019

GUERBET : Nombre d’actions et de droits de vote composant le capital de la société au 31 octobre 2019En application de l’article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les sociétés dont des actions sont admises aux négociations sur un marché réglementé publient sur leur site Internet et transmettent à l’AMF, à la fin de chaque mois, le nombre total de droits de vote et le nombre d’actions composant le capital de la société s’ils ont varié par rapport à ceux publiés antérieurement. Ces sociétés sont réputées remplir l’obligation prévue au I de l’article L. 233-8 du code de commerce.1 calculé, comme prévu au dernier alinéa de l’article 223-11 du règlement général, sur la base de l’ensemble des actions auxquelles sont attachés...

UAB Ignitis Grupė (hereinafter – the Company or Ignitis Group) identification code 301844044, registered office placed at Žvejų str. 14, Vilnius, Republic of Lithuania. The total nominal value of issued bonds 600 000 000 EUR; ISIN codes XS1646530565; XS1853999313.Preliminary financial data of Ignitis Group for 10 months of 2019:In January-October 2019, Ignitis Group generated revenue of EUR 1302.9 million, which is 29.6% more if compared to the same period in 2018 (EUR 1005.3 million). The Company’s revenue has grown mostly due to the increase in the electricity trading turnover of UAB Ignitis subsidiary in Poland Geton Energy.The adjusted EBITDA indicator of the Company in January-October 2019 was equal to EUR 217.2 million, i.e. 15.3% more compared to a respective period of 2018 (EUR 188.3 million). The adjusted EBITDA indicator...

UAB „Ignitis grupė“ (toliau – „Ignitis grupė“ ir Bendrovė), juridinio asmens kodas: 301844044, registruotos buveinės adresas: Žvejų g. 14, Vilnius. Bendra UAB „Ignitis grupė“ išleistų obligacijų nominali vertė 600 000 000 EUR; ISIN kodai: XS1646530565; XS1853999313.2019 metų 10 mėnesių preliminarūs „Ignitis grupės“ finansiniai duomenys:„Ignitis grupės“ pajamos 2019 m. sausio-spalio mėn. siekė 1 302,9 mln. eurų ir buvo 29,6 proc. didesnės palyginus su atitinkamu laikotarpiu 2018 m. (1 005,3 mln. eurų). Grupės pajamas kaip ir ankstesniais šių metų mėnesiais reikšmingiausiai augino „Ignitis“ dukterinės įmonės Lenkijoje „Geton Energy“ išaugusios didmeninės prekybos apyvartos biržoje.  Bendrovės koreguotas EBITDA rodiklis 2019 m. sausio-spalio mėn. siekė 217,2 mln. eurų – 15,3 proc. daugiau nei atitinkamu laikotarpiu 2018 m. (188,3 mln. eurų)....

Please find the attached VILNIAUS BALDAI AB audited consolidated and company’s financial statements for the year 2019 ended 31 August 2019 with independent auditor’s report.Enclosed:1. Confirmation of responsible persons;2. Independent auditor’s report, consolidated annual report, consolidated and company’s financial statements for the year 2019 ended 31 August 2019.Additional information:Chief Financial OfficerEdgaras KabečiusPhone No: +370 5 2525700AttachmentVILNIAUS BALDAI AB consolidated and companys financial statements for the FY19 ended 31 August 2019

Pateikiamos AB “VILNIAUS BALDAI” audituotos konsoliduotos ir bendrovės 2019 metų, pasibaigusių 2019 m. rugpjūčio 31d., finansinės ataskaitos.Pridedama:1. Atsakingų asmenų patvirtinimas;2. Nepriklausomo auditoriaus išvada, metinis konsoliduotas pranešimas, konsoliduotos ir bendrovės 2019 metų, pasibaigusių 2019 m. rugpjūčio 31 d., finansinės ataskaitos.Kontaktinis asmuo:Finansų vadovasEdgaras KabečiusTel +370 (5) 2525700PriedasAB VILNIAUS BALDAI konsoliduotos ir bendroves finansines ataskaitos uz 2019 m., pasibaigusios 2019 rugpjucio 31 d.

TITUSVILLE, Fla., Nov. 29, 2019 (GLOBE NEWSWIRE) — The Apple Rush Company, Inc. (OTC PINK: APRU) (the “company”) provides an update for 2020 through a letter to shareholders.  Tony Torgerud, CEO of Apple Rush, stated, “We have been quiet the last couple of months while preparing for the explosive growth plans for Apple Rush in 2020. This growth includes an operational plan that will expand distribution to the entire country and to several International locations as well. We have spent an enormous amount of time and energy working with our team to build the foundation for the future.”  Our new COO, to be officially announced in the near future added, “Charging into 2020 with such a diverse portfolio and on the cusp of such powerful emerging markets, I believe APRU will be making waves and growing significantly as a profitable leader...

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has submitted to the U.S. Food and Drug Administration (“FDA”) the first portions of its Biologics License Application (“BLA”) for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma under the FDA’s Rolling Review process.In August 2018, naxitamab, which is an anti-GD2 monoclonal antibody, received Breakthrough Therapy Designation by the FDA, which facilitates frequent interactions with the FDA review team. The Rolling Review process allows Y-mAbs to submit individual portions of the BLA for...